TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT03259867: Combination of TATE and PD-1 Inhibitor in Liver Cancer

Sponsor: Teclison Ltd. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 54 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT03259867 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03259867 Rescue Dossier →